CXCR3 and fibrosis: However, the proportion of CXCR3+ eTregs was lower in the HF+++ group (37.4 ± 5.9%) than in patients with milder fibrosis (HF+/- and HF++, as compared to HF+++) (51.7 ± 2%; p = 0.009) and was not affected by SplM (Fig 2D).